News

VPM receives 30 Million Euro Funding from the European Investment Bank for VPM1002 tuberculosis vaccine development in Africa. Read more or Stream the ceremony!

First participants receive VPM1002 in a late-stage phase III clinical trial in Germany. Read more!

First participant enrolled in Phase III clinical trial of VPM1002 focused on healthcare workers battling the COVID-19 pandemic. Read more!

In Germany, a vaccine candidate will be tested for its effectiveness against infections with the novel corona virus. Read more!

Vakzine Projekt Management GmbH: First volunteer enrolled in Phase II/III Study of SIIPL Tdap vaccine in Comparison with Boostrix® in Healthy Participants. More!

Press release on February 20, 2020: Modified tuberculosis vaccine as a therapy for cancer of the bladder. A therapy with VPM1002 is effective for bladder cancer patients. Please klick here for the whole release!

The pivotal phase III infant vaccine trial was accepted by the African Vaccine Regulatory Forum (AVAREF) for a joint review process. The meeting has taken place from 22-24^th of January 2020 in Nairobi, Kenya.

The VPM employee Alexandra Hierweger received the Uwe Koch-Gromus-PhD-Promotionspreis 2019 for her PhD thesis with the title 'Influence of influenza A virus infections on the maternal immune system during pregnancy'. The ceremony took place on 6^th of December 2019 at the University Medical Center Hamburg-Eppendorf.

VPM will be participant and speaker at the TB vaccine conference in Les Diablerets, Switzerland, taking place from 27 – 29 January 2020.

The priMe Investigator meeting has taken place from 27-28th of November 2019 in Dar es Salaam, Tanzania.